The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; 3 of the 7 sources its claims cite were checked for support.
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
Open accessAbstract
BACKGROUND: Lenalidomide plus dexamethasone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation. We sought to determine whether the addition of daratumumab would significantly reduce the risk of disease progression or death in this population. METHODS: We randomly assigned 737 patients with newly diagnosed multiple myeloma who were ineligible for autologous stem-cell transplantation to receive daratumumab plus lenalidomide and dexamethasone (daratumumab group) or lenalidomide and dexamethasone alone (control group). Treatment was to continue until the occurrence of disease progression or unacceptable side effects. The primary end point was progression-free survival. RESULTS: white cells) (P<0.001). The most common adverse events of grade 3 or 4 were neutropenia (50.0% in the daratumumab group vs. 35.3% in the control group), anemia (11.8% vs. 19.7%), lymphopenia (15.1% vs. 10.7%), and pneumonia (13.7% vs. 7.9%). CONCLUSIONS: Among patients with newly diagnosed multiple myeloma who were ineligible for autologous stem-cell transplantation, the risk of disease progression or death was significantly lower among those who received daratumumab plus lenalidomide and dexamethasone than among those who received lenalidomide and dexamethasone alone. A higher incidence of neutropenia and pneumonia was observed in the daratumumab group. (Funded by Janssen Research and Development; MAIA ClinicalTrials.gov number, NCT02252172.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
24 Own result · 5 Own method · 4 Own interpretation · 2 Partly supported · 1 Supported so far · 1 No full text of the sources · accuracy not yet measured
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The phase 3 Southwest Oncology Group (SWOG) S0777 trial of lenalidomide plus dexamethasone with or without bortezomib in patients with newly diagnosed myeloma for whom immediate autologous stem-cell transplantation was not indicated showed that the triplet combination resulted in longer progression-free survival (median, 41 months vs. 29 months; hazard ratio, 0.74), including among patients who”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Discussion
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Lenalidomide plus dexamethasone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation.”
- Also stated in: § CONCLUSIONS · boosted
“these findings established the regimen of lenalidomide and dexamethasone as standard of care.”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Abstract > BACKGROUND
What the sources say
- Not checked — no full text of the sourcecites [5] source
- Supportedcites [17] source
The Introduction calls lenalidomide plus dexamethasone one of the standards of care for newly diagnosed multiple myeloma and specifically lists it as a treatment option for patients ineligible for autologous stem-cell transplant. This directly supports the citing sentence. (LLM, conf=0.94)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § CONCLUSIONS · boosted
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, in the CASTOR and POLLUX trials, among patients with relapsed or refractory multiple myeloma who had a high-risk cytogenetic profile, substantial benefits with respect to progression-free survival and minimal residual disease with daratumumab plus standard-of-care regimens were observed after a longer follow-up period.”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Discussion
What the sources say
- Partly supportedcites [16] sourceExperimental — accuracy not yet measured
The Efficacy section (p. 9) says the longer-follow-up POLLUX progression-free survival benefit was maintained across cytogenetic-risk subgroups, and the Discussion (p. 11) reports higher MRD-negativity rates overall. It does not establish an MRD benefit specifically in high-risk patients. Its CASTOR comparison (Discussion, p. 11) concerns patients with one prior therapy, not the high-risk cytogenetic subgroup. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [25] source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Prespecified subgroup analyses of progression-free survival confirmed the superiority of the daratumumab regimen over the control regimen across all subgroups, except in the subgroup of patients who had hepatic impairment at baseline (Fig. 2).”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Results > EFFICACY
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The progression-free survival benefit was maintained among patients 75 years of age or older (hazard ratio, 0.63; 95% CI, 0.44 to 0.92).”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Results > EFFICACY
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among the patients who had a response (partial response or better), 80.3% (95% CI, 75.1 to 84.5) in the daratumumab group and 65.7% (95% CI, 58.6 to 71.8) in the control group sustained the response for 30 months.”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Results > EFFICACY
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Daratumumab plus lenalidomide and dexamethasone was associated with a higher incidence of neutropenia and infections.”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Discussion
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Negative status for minimal residual disease was associated with longer progression-free survival than positive status, regardless of the trial treatment (Fig. S3 in the Supplementary Appendix).”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Results > EFFICACY
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The percentage of patients with an overall response was 92.9% in the daratumumab group and 81.3% in the control group (P<0.001).”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Results > EFFICACY
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The incidence of infections of any grade was 86.3% in the daratumumab group and 73.4% in the control group; the incidence of grade 3 or 4 infections was 32.1% in the daratumumab group and 23.3% in the control group.”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Results > SAFETY
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 7
- Probably not a substantial claim. 3
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Our trial population was notably older; 99% of the patients were 65 years of age or older, and 44% were 75 years of age or older.”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median progression-free survival was not reached in the daratumumab group and was 31.9 months (95% CI, 28.9 to not reached) in the control group.”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Results > EFFICACY
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In this trial involving patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation, the addition of daratumumab to lenalidomide and dexamethasone resulted in significantly longer progression-free survival, a higher response rate, an increased depth of response, and a longer duration of response than lenalidomide and dexamethasone alone.”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Discussion
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Randomization was stratified according to International Staging System disease stage (I vs. II vs. III, with higher stages indicating more severe disease) (see Table S1 in the Supplementary Appendix for details on the staging criteria), geographic region (North America vs. other), and age (<75 vs. ≥75 years).”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Methods > RANDOMIZATION AND TREATMENT
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“We estimated that a sample of 730 patients would provide the trial with 80% power to detect a risk of disease progression or death that was 25% lower with daratumumab plus lenalidomide and dexamethasone than with lenalidomide and dexamethasone alone, using a log-rank test at a two-sided alpha level of 0.05.”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Methods > STATISTICAL ANALYSIS
hedgeddirectn = 730- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The primary analysis was performed in the intention-to-treat population, which included all patients who underwent randomization.”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Methods > STATISTICAL ANALYSIS
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The percentage of patients who discontinued treatment because of these adverse events was low in our trial and was consistent with the safety profile observed in the POLLUX and ALCYONE trials, the latter of which represents a similar population of patients with newly diagnosed myeloma who were ineligible for stem-cell transplantation.”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“We randomly assigned 737 patients with newly diagnosed multiple myeloma who were ineligible for autologous stem-cell transplantation to receive daratumumab plus lenalidomide and dexamethasone (daratumumab group) or lenalidomide and dexamethasone alone (control group).”
- Also stated in: § PATIENTS AND TREATMENT · plain
“A total of 737 patients were randomly assigned — 368 to the daratumumab group and 369 to the control group.”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Abstract > METHODS
plainn = 737- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § PATIENTS AND TREATMENT · plain
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although patients in the daratumumab group received treatment for a longer period of time, they received less lenalidomide than the control group, possibly owing to a higher incidence of adverse events that led to dose discontinuations or dose modifications in this group.”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Discussion
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“However, the incidence of grade 3 or 4 infections was 29% with lenalidomide and dexamethasone in the primary analysis of the FIRST trial,5 which was consistent with the incidence in our trial (32.1% in the daratumumab group and 23.3% in the control group).”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Discussion
What the sources say
- Not checked — no full text of the sourcecites [5] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“DRd is approved for patients with newly diagnosed myeloma based on the results of an international multicenter randomized trial which showed benefit over lenalidomide plus dexamethasone (Rd).97”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [97]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Daratumumab, an anti-CD38–targeting monoclonal antibody (mAb), is a cornerstone of standard-of-care MM regimens with demonstrated survival benefit across all lines.9–14”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [10]
Experimental — accuracy not yet measuredIn the citing paper
“Meta-analyses suggest that indefinite maintenance therapy is superior in terms of survival outcomes36”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [36]
Citations
Cites
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978
Self-citationKumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationInternational Staging System for Multiple Myeloma
Greipp, P. R., Miguel, J. S., Durie, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J. A., Avet-Loiseau, H., Kyle, R. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.242 · Cited by 2,974
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationPalumbo, A. P., & Anderson, K. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,382
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606038 · Cited by 1,522 · cited 2×
“‖ Cytogenetic risk was based on fluorescence in situ hybridization or karyotype analysis; patients who had a high-risk cytogenetic profile had at least one high-risk abnormality (del17p, t[14;16], or t[4;14]).”
BackgroundMethodSelf-citationDaratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445
Self-citationTargeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506348 · Cited by 1,117
Self-citationde Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037
Rajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036
Self-citation
Cited by
Sorted by citations
Items 201–300 of 1,013
Daratumumab: A review of current indications and future directions
Hill, E., Morrison, C., & Kazandjian, D. G. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.01.008 · Cited by 28
Ferla, V., Antonini, E., Perini, T., Farina, F., Masottini, S., Malato, S., Marktel, S., Stanghellini, M. T. L., Tresoldi, C., Ciceri, F., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.932852 · Cited by 33
Medhekar, R., Ran, T., Fu, A. Z., Patel, S., & Kaila, S. (2022) · BMC Cancer · doi:10.1186/s12885-022-09980-9 · Cited by 29
“Notably, the treatment landscape for this patient population continues to evolve; for instance, based on the results of the recent phase 3 MAIA study [10], daratumumab in combination with lenalidomide and dexamethasone (D-Rd) has also been recommended by the NCCN guidelines as a preferred regimen in transplant-ineligi…”
BackgroundResultFonseca, R., Facon, T. T. F., Hashim, M., Nair, S. C., He, J., Ammann, E. M., Lam, A., Wildgust, M. A., & Kumar, S. K. (2023) · The Oncologist · doi:10.1093/oncolo/oyad053 · Cited by 28
Self-citationShragai, T., Gatt, M. E., Lavie, N., et al. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13535 · Cited by 27
“Previous treatment lines, n; median (range) 1 (1-6)”
BackgroundInfluentialSequencing multiple myeloma therapies with and after antibody therapies
van de Donk, N. W. C. J. (2020) · Hematology · doi:10.1182/hematology.2020000109 · Cited by 27
Kitadate, A., Terao, T., Narita, K., et al. (2021) · Cancer Science · doi:10.1111/cas.15073 · Cited by 27
Noori, S., Verkleij, C. P. M., Zajec, M., Langerhorst, P., Bosman, P. W. C., de Rijke, Y. B., Zweegman, S., VanDuijn, M. M., Luider, T. M., van de Donk, N. W. C. J., et al. (2021) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2021-0399 · Cited by 28
Immunotherapy in multiple myeloma
Jadoon, Y., & Siddiqui, M. A. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100468 · Cited by 33
Ocio, E. M., Perrot, A., Bories, P., Miguel, J. F. S., Blau, I. W., Karlin, L., Martínez‐López, J., Wang, S., Bringhen, S., Marcatti, M., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01936-7 · Cited by 27
Self-citationZweegman, S., Stege, C. A. M., Haukås, E., Schjesvold, F. H., Levin, M., Waage, A., Leys, R. B. L., Klein, S. K., Szatkowski, D., Axelsson, P., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.240374 · Cited by 27
Immunotherapeutic and Targeted Approaches in Multiple Myeloma
Nadeem, O., Tai, Y., & Anderson, K. C. (2020) · ImmunoTargets and Therapy · doi:10.2147/itt.s240886 · Cited by 26
Mohyuddin, G. R., Koehn, K., Abdallah, A.-O. A., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26166 · Cited by 26
“changed by adding daratumumab up-front rather than reserving it at progression, where it has been demonstrated to be effective already.(23,32) In this setting, either OS, quality of life, or an endpoint incorporating subsequent treatments such as the “second progressionfree survival or PFS-2(33)” should be used.”
BackgroundSelf-citationERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment
Liu, J., Hideshima, T., Xing, L., Wang, S., Zhou, W., Samur, M., Sewastianik, T., Ogiya, D., An, G., Gao, S., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg2697 · Cited by 27
Immune checkpoint inhibitors for the treatment of myeloma: novel investigational options
Calvez, B. L., Moreau, P., & Touzeau, C. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1955103 · Cited by 28
Self-citationPuig, N., Flores-Montero, J. A., Burgos, L., Cedena, M., Cordón, L., Pérez, J.-J., Sanoja-Flores, L., Manrique, I., Rodríguez‐Otero, P., Rosiñol, L., et al. (2021) · Cancers · doi:10.3390/cancers13194924 · Cited by 26
Atrash, S., Thompson‐Leduc, P., Tai, M., Kaila, S., Gray, K. S., Ghelerter, I., Lafeuille, M., Lefèbvre, P., & Rossi, A. (2021) · BMC Cancer · doi:10.1186/s12885-021-08881-7 · Cited by 26
“In recent trials of daratumumab among newly-diagnosed patients, the proportion of patients achieving very good partial response or better ranged from 73 to 83% [10, 11, 24].”
BackgroundAbecassis, A., Roders, N., Fayon, M., et al. (2022) · eJHaem · doi:10.1002/jha2.479 · Cited by 26
Past, Present, and a Glance into the Future of Multiple Myeloma Treatment
Elbezanti, W. O., Challagundla, K. B., Jonnalagadda, S. C., Budak-Alpdoǧan, T., & Pandey, M. K. (2023) · Pharmaceuticals · doi:10.3390/ph16030415 · Cited by 36
“Daratumumab 2019 NTE NDMM IRs, URTI, diarrhea, constipation, peripheral edema, nausea, fatigue, asthenia, dyspnea, pyrexia, muscle spasms, and PSN MAIA NTC02252172 [66,77,78]”
Young Myeloma Patients: A Systematic Review of Manifestations and Outcomes
Tanguay, M., Dagenais, C., LeBlanc, R., Ahmad, I., Claveau, J., & Roy, J. (2023) · Current Oncology · doi:10.3390/curroncol30060396 · Cited by 27
“For transplant ineligible patients, initial treatments with combinations of VRd and DRd followed by maintenance are standards of care [46,47].”
BackgroundMolecular dynamics of targeting CD38 in multiple myeloma
Malavasi, F., Faini, A. C., Morandi, F., Castella, B., Incarnato, D., Oliviero, S., Horenstein, A. L., Massaia, M., van de Donk, N. W. C. J., & Richardson, P. G. G. (2021) · British Journal of Haematology · doi:10.1111/bjh.17329 · Cited by 26
Frontline therapy for newly diagnosed patients with multiple myeloma
Jung, S., Jo, J., Song, G., Ahn, S., Yang, D., Ahn, J., Kim, H., & Lee, J. (2020) · Blood Research · doi:10.5045/br.2020.s007 · Cited by 25
“The interim analysis results of a randomized phase III trial (MAIA) comparing daratumumab, lenalidomide, and dexamethasone (DRd) with Rd in transplant-ineligible patients have been reported [44].”
BackgroundMonoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True
D’Agostino, M., Innorcia, S., Boccadoro, M., & Bringhen, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218192 · Cited by 28
“In the phase III MAIA trial, 737 NDMM NTE patients received Rd with or without daratumumab [52].”
BackgroundBCL2 Family Inhibitors in the Biology and Treatment of Multiple Myeloma
Gupta, V. A., Ackley, J. C., Kaufman, J. L., & Boise, L. (2021) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s245191 · Cited by 27
Mizuhara, K., Shimura, Y., Tsukamoto, T., Kanai, A., Kuwahara‐Ota, S., Yamaguchi, J., Muramatsu, A., Okamoto, H., Katsuragawa‐Taminishi, Y., Kawaji‐Kanayama, Y., et al. (2023) · British Journal of Haematology · doi:10.1111/bjh.19049 · Cited by 24
Dold, S. M., Möller, M., Ihorst, G., et al. (2020) · Haematologica · doi:10.3324/haematol.2020.254235 · Cited by 24
SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma
Kassem, S., Diallo, B., El-Murr, N., Carrié, N., Tang, A., Fournier, A., Bonnevaux, H., Nicolazzi, C., Cuisinier, M., Reguigne-Arnould, I., et al. (2022) · Blood · doi:10.1182/blood.2021012448 · Cited by 24
Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis
Minnema, M. C., Dispenzieri, A. A., Merlini, G., Comenzo, R. L., Kastritis, E., Wechalekar, A. D., Grogan, M. A., Witteles, R. M., Ruberg, F. L., Maurer, M. S., et al. (2022) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.08.011 · Cited by 26
Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences
Morè, S., Offidani, M., Corvatta, L., Petrucci, M. T., & Fazio, F. (2023) · Cancers · doi:10.3390/cancers15112948 · Cited by 26
“Treatment included six induction cycles with VRd plus belamaf 2.5 mg/kg every 8 weeks, high dose melphalan and ASCT, followed by consolidation with two cycles with Bela-VRd and maintenance with lenalidomide until progression plus belamaf for 2 years.”
BackgroundInfluentialNewly Diagnosed Myeloma in 2020
Moreau, P., Touzeau, C., Vij, R., Goldsmith, S. R., & Rosko, A. E. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280221 · Cited by 24
Self-citationvan de Donk, N. W. C. J., Rasche, L., Sidana, S., Zweegman, S., & Garfall, A. L. (2024) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-24-0124 · Cited by 26
Naicker, S. D., Feerick, C. L., Lynch, K., Swan, D., McEllistrim, C., Henderson, R. B., Leonard, N. A., Treacy, O., Natoni, A., Rigalou, A., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2020.1859263 · Cited by 23
Self-citationRapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review
Nishida, H. (2021) · Cancers · doi:10.3390/cancers13112712 · Cited by 23
“Humanized anti-CD38 mAbs, currently available for the treatment of MM, include intravenous daratumumab (DARA) [25–37], subcutaneous DARA [75], and isatuximab [38–44] (Figure 1).”
BackgroundRequirements for operational cure in multiple myeloma
Mohty, M., Avet‐Loiseau, H., & Harousseau, J. (2021) · Blood · doi:10.1182/blood.2021012854 · Cited by 24
McCaughan, G. J. B., Gandolfi, S., Moore, J. J., & Richardson, P. G. G. (2022) · British Journal of Haematology · doi:10.1111/bjh.18295 · Cited by 26
Immune therapy: a new therapy for acute myeloid leukemia
Tian, C., & Chen, Z. (2022) · Blood Science · doi:10.1097/bs9.0000000000000140 · Cited by 23
A rational approach to functional high-risk myeloma.
Gay, F., Bertuglia, G., & Mina, R. (2023) · Hematology. American Society of Hematology. Education Program · doi:10.1182/hematology.2023000443 · Cited by 21
Plesner, T., van de Donk, N. W. C. J., & Richardson, P. G. G. (2020) · Cells · doi:10.3390/cells9020378 · Cited by 23
Self-citationKiss, S., Gede, N., Hegyi, P., Nagy, B., Deák, R., Dembrovszky, F., Bunduc, S., Erőss, B., Leiner, T., Szakács, Z., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-01440-x · Cited by 23
Siddiqui, B. A., Chapin, B. F., Jindal, S., Duan, F., Basu, S., Yadav, S. S., Gu, A.-D., Espejo, A. B., Kinder, M., Pettaway, C. A., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006262 · Cited by 22
Self-citationGay, F., Marchetti, E., & Bertuglia, G. (2025) · Hematological Oncology · doi:10.1002/hon.70067 · Cited by 30
Melflufen for relapsed and refractory multiple myeloma
Oriol, A., Larocca, A., Leleu, X. P., Hájek, R., Hassoun, H., Rodríguez‐Otero, P., Paner, A., Schjesvold, F. H., Gullbo, J., & Richardson, P. G. G. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1808884 · Cited by 24
Self-citationAlmaani, S. J., Parikh, S. V., Satoskar, A. A., et al. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.05.008 · Cited by 22
Tan, C. R. C., Derkach, A., Nemirovsky, D., Ciardiello, A. K., Diamond, B. T., Hultcrantz, M. L., Hassoun, H., Mailankody, S., Shah, U. A., Maclachlan, K. H., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00882-y · Cited by 23
Self-citationMinimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives
Mina, R., Oliva, S., & Boccadoro, M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072142 · Cited by 24
The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma
Becnel, M., & Lee, H. C. (2020) · Therapeutic Advances in Hematology · doi:10.1177/2040620720979813 · Cited by 24
Treatment of Patients with Newly-Diagnosed Multiple Myeloma
Bolaman, A. Z., & Turgutkaya, A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.105774 · Cited by 21
Manier, S., Lambert, J., Hulin, C., Macro, M., Laribi, K., Araujo, C., Pica, G. M., Touzeau, C., Godmer, P., Slama, B., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00280-3 · Cited by 23
Self-citationGiles, H. V., Wechalekar, A. D., & Pratt, G. (2022) · British Journal of Haematology · doi:10.1111/bjh.18226 · Cited by 22
Ryu, Y. K., Ricker, E., Soderquist, C. R., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164928 · Cited by 21
“6% in Rd [14] and in relapsed/refractory MM as per the POLLUX trial with the overall response rate (ORR) of 92.”
MethodNew Developments in Myeloma Treatment and Response Assessment
Kraeber‐Bodéré, F., Jamet, B., Bezzi, D., Zamagni, E., Moreau, P., & Nanni, C. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264972 · Cited by 21
“For transplant-ineligible patients, outstanding outcomes have been reported when daratumumab was combined with lenalidomide and dexamethasone ( 28,29 ).”
BackgroundSelf-citationVaxman, I., Visram, A., Kumar, S. K., Dispenzieri, A. A., Buadi, F. K., Dingli, D., Lacy, M. Q., Muchtar, E., Kapoor, P., Hogan, W. J., et al. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-01159-9 · Cited by 20
Self-citationChitty, D. W., Hartley-Brown, M. A., Abate, M. T., Thakur, R., Wanchoo, R., Jhaveri, K. D., & Nair, V. V. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa361 · Cited by 21
Efficacy of Intravenous Immunoglobulin for Preventing Infections in Patients with Multiple Myeloma
Lancman, G., Lozada, K. S., Athar, N., Jacobs, S. E., Doucette, J. T., Cho, H. J., Jagannath, S., Madduri, D., Parekh, S. S., Richard, S., et al. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.12.026 · Cited by 22
Frerichs, K. A., Verkleij, C. P. M., Dimopoulos, M. A., Soto, J. A. M., Zweegman, S., Young, M. H., Newhall, K. J., Mutis, T., & van de Donk, N. W. C. J. (2021) · Cancers · doi:10.3390/cancers13102452 · Cited by 21
Vitkon, R., Netanely, D., Levi, S., Ziv‐Baran, T., Ben-Yzak, R., Katz, B., Benyamini, N., Trestman, S., Mittelman, M., Cohen, Y. C., et al. (2021) · Therapeutic Advances in Hematology · doi:10.1177/20406207211035272 · Cited by 22
Historia de la historia del arte: el camino de una ciencia
Kultermann, U. (1996) · Dialnet (Universidad de la Rioja) · Cited by 21
Current and Novel Alkylators in Multiple Myeloma
Schjesvold, F. H., & Oriol, A. (2021) · Cancers · doi:10.3390/cancers13102465 · Cited by 22
CD38-Directed Therapies for Management of Multiple Myeloma
Hashmi, H., Husnain, M., Khan, A. Y., & Usmani, S. Z. (2021) · ImmunoTargets and Therapy · doi:10.2147/itt.s259122 · Cited by 20
“001) in the Rd group.(23) Based on the encouraging safety and efficacy outcomes from these first line studies, daratumumab based triplet therapy is now routinely being used in the upfront setting for treatment of the newly diagnosed transplant ineligible patients with multiple myeloma.”
BackgroundSelf-citationRaje, N. S., Mateos, M., Iida, S., & Reece, D. E. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00804-y · Cited by 20
“The inclusion of daratumumab within these combinations was based on results from the phase 3 MAIA and ALCYONE studies, which demonstrated longer PFS when combined with lenalidomide-dexamethasone or bortezomib-melphalan-prednisone, respectively [30, 32].”
BackgroundResultSelf-citationRole of daratumumab in the frontline management of multiple myeloma: a narrative review
Yadav, S., Gundeti, S., Bhave, A. A., Deb, U., Dixit, J., & Mishra, K. (2023) · Expert Review of Hematology · doi:10.1080/17474086.2023.2246651 · Cited by 20
Teclistamab‐cqyv in multiple myeloma
Martino, E. A., Bruzzese, A., Labanca, C., Mendicino, F., Lucia, E., Olivito, V., Neri, A., Morabito, F., Vigna, E., & Gentile, M. (2023) · European Journal Of Haematology · doi:10.1111/ejh.14121 · Cited by 22
Mai, E. K., Goldschmidt, H., Miah, K., Bertsch, U., Besemer, B., Hänel, M., Krzykalla, J., Fenk, R. R., Schlenzka, J., Munder, M., et al. (2024) · The Lancet Haematology · doi:10.1016/s2352-3026(23)00366-6 · Cited by 20
Self-citationO'Dwyer, M. E., Henderson, R. B., Naicker, S. D., Cahill, M. R., Murphy, P. T., Mykytiv, V., Quinn, J., McEllistrim, C., Krawczyk, J., Walsh, J., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000010 · Cited by 21
Self-citationEvolving Role of Daratumumab: From Backbencher to Frontline Agent
Jain, A., & Ramasamy, K. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.03.010 · Cited by 20
Immunotherapy in Multiple Myeloma—Time for a Second Major Paradigm Shift
Mohan, M., Hari, P., & Dhakal, B. (2021) · JCO Oncology Practice · doi:10.1200/op.21.00032 · Cited by 21
Mohyuddin, G. R., Aziz, M., McClune, B. L., Abdallah, A.-O. A., & Qazilbash, M. H. (2019) · European Journal Of Haematology · doi:10.1111/ejh.13374 · Cited by 19
Hu, X., Wu, C.-H., Cowan, J. M., et al. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04704-8 · Cited by 19
Thangaraj, J. L., Jung, S., Vo, M.-C., Chu, T.-H., Phan, M. T., Lee, K., Ahn, S., Kim, M., Song, G., Ahn, J., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03322-1 · Cited by 18
“Moreover, lenalidomide in combination with monoclonal antibodies enhances the cytotoxicity of NK cells [1, 2, 24, 30].”
BackgroundNatural Killer Cells: A Promising Kit in the Adoptive Cell Therapy Toolbox
Xiao, J., Zhang, T., Gao, F., Zhou, Z., Shu, G., Zou, Y., & Yin, G. (2022) · Cancers · doi:10.3390/cancers14225657 · Cited by 19
Mollee, P. N., Reynolds, J., Janowski, W., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023012539 · Cited by 19
“3,6 However, in many jurisdictions, the VMP regimen is not widely used, with the combination of bortezomib, cyclophosphamide, and dexamethasone (VCD) being favored because of concerns about the genotoxicity of melphalan and dif fi culty of dosing melphalan in renal impairment.”
Self-citationFiala, M. A., Foley, N. C., Zweegman, S., Vij, R., & Wildes, T. M. (2020) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2020.03.005 · Cited by 20
Giri, S., Aryal, M. R., Yu, H., Grimshaw, A. A., Pathak, R., Huntington, S. P., & Dhakal, B. (2020) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2020.05.013 · Cited by 19
“In addition to providing results on both efficacy and safety outcomes, our study also incorporates the recently published practice changing MAIA study(35), hence generating a more updated summative evidence on this topic.”
ResultJackson, G. H., Pawlyn, C., Cairns, D. A., Striha, A., Collett, C., Waterhouse, A., Jones, J. R., Wilson, J. N., Taylor, C., Kishore, B., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16945 · Cited by 19
“195 (2) 113 (12) 55 (12) 35 (12) 17 (15) 9 (19) 7 (21) 1 (26) 0 (27) 222 (1) 142 (10) 90 (10) 65 (11) 40 (20) 20 (28) 12 (33) 4 (38) 0 (42) Number at risk (number censored) CTDa CRDa 0 12 24 36 48 60 72 84 96 108”
BackgroundSunami, K., Suzuki, K., Ri, M., Matsumoto, M., Shimazaki, C., Asaoku, H., Shibayama, H., Ishizawa, K., Takamatsu, H., Ikeda, T., et al. (2020) · Cancer Science · doi:10.1111/cas.14657 · Cited by 19
“Deep vein thrombosis 1 (33) 1 (33) 0 0 1 (4) 0”
BackgroundInfluentialLuo, M., Usmani, S. Z., Mateos, M., Nahi, H., Chari, A., Miguel, J. F. S., Touzeau, C., Suzuki, K., Kaiser, M., Carson, R. L., et al. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1771 · Cited by 19
Self-citationThe evolving status of immunotherapies in multiple myeloma: the future role of bispecific antibodies
Swan, D., Routledge, D. J. M., & Harrison, S. J. (2021) · British Journal of Haematology · doi:10.1111/bjh.17805 · Cited by 19
Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice
Gozzetti, A., Raspadori, D., Bacchiarri, F., Sicuranza, A., Pacelli, P., Ferrigno, I., Tocci, D., & Bocchia, M. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030120 · Cited by 19
Moreau, P., Hébraud, B., Facon, T. T. F., Leleu, X. P., Hulin, C., Hashim, M., Hu, Y., Caillot, D., Benboubker, L., Zweegman, S., et al. (2020) · Immunotherapy · doi:10.2217/imt-2020-0266 · Cited by 18
Self-citationEveillard, M., Korde, N., Ciardiello, A. K., et al. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.01.021 · Cited by 18
Pathogenesis and treatment of multiple myeloma bone disease
Hiasa, M., Harada, T., Tanaka, E. I., & Abe, M. (2021) · Japanese Dental Science Review · doi:10.1016/j.jdsr.2021.08.006 · Cited by 18
Efficace, F., Cottone, F., Sparano, F., Caocci, G., Vignetti, M., & Chakraborty, R. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.01.009 · Cited by 19
Girmenia, C., Cavo, M., Corso, A., Raimondo, F. D., Musto, P., Offidani, M., Petrucci, M. T., Rosato, A., & Barosi, G. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103623 · Cited by 19
Multiple Myeloma: Impact of Time to Transplant on the Outcome
Kumar, L., Hussain, M. M., Chethan, R., Sahoo, R. K., Malik, P. S., Sharma, O. D., Mathew, A., Jha, A., Gupta, R., Sharma, A., et al. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.04.020 · Cited by 18
Royle, K., Coulson, A. B., Ramasamy, K., Cairns, D. A., Hockaday, A., Quezada, S. A., Drayson, M. T., Kaiser, M., Owen, R. G., Auner, H. W., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-063037 · Cited by 17
Costa, B. A., Mouhieddine, T. H., Ortiz, R. J., & Richter, J. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104040 · Cited by 18
Immunotherapy in Acute Leukemias: Past Success Paves the Way for Future Progress
Chergui, A., & Reagan, J. L. (2023) · Cancers · doi:10.3390/cancers15164137 · Cited by 18
“Daratumumab, an anti-CD38 monoclonal antibody, which was studied and approved for the front-line treatment of multiple myeloma [60], has shown pre-clinical efficacy in T-ALL xenograft models [59,61].”
BackgroundPatient-Reported Outcomes in Phase 3 Clinical Trials for Blood Cancers: A Systematic Review
Patel, K. K., Ivanov, A., Jocelyn, T., Hantel, A., Garcia, J. S., & Abel, G. A. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.14425 · Cited by 22
Okazuka, K., Ishida, T., Nashimoto, J., Uto, Y., Sato, K., Miyazaki, K., Ogura, M., Yoshiki, Y., Abe, Y., Tsukada, N., et al. (2019) · European Journal Of Haematology · doi:10.1111/ejh.13349 · Cited by 18
Bai, Z., Liu, X., Guan, Q., Ding, N., Wei, Q., Tong, B., Zhao, M., Zhang, W., & Ma, L. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.108886 · Cited by 19
Characterisation and prognostic impact of immunoparesis in relapsed multiple myeloma
Chakraborty, R., Rybicki, L. A., Nakashima, M. O., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16488 · Cited by 18
“As mAbs are currently being incorporated in the front-line treatment of MM (Mateos et al., 2018; Facon et al., 2019) and can lead to prolonged suppression of polyclonal immunoglobulins, the prognostic impact of immunoparesis at relapse will need to be revisited in future as the treatment landscape…”
BackgroundUpdated Perspectives on the Management of Multiple Myeloma in Older Patients: Focus on Lenalidomide
Schoenbeck, K. L., & Wildes, T. M. (2020) · Clinical Interventions in Aging · doi:10.2147/cia.s196087 · Cited by 17
“3 clinical trials were cytopenias, particularly neutropenia and thrombocytopenia.(17,20,22,23,34,36) This is most likely to occur within the first several months of treatment with lenalido-”
BackgroundLemieux, C., Muffly, L. S., Rezvani, A. R., Lowsky, R., Iberri, D. J., Craig, J. K., Frank, M. J., Johnston, L., Liedtke, M., Negrin, R. S., et al. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-01026-7 · Cited by 18
Cohen, Y. C., Oriol, A., Wu, K. L., Lavi, N., Vlummens, P., Jackson, C. C., Garvin, W., Carson, R. L., Crist, W. A., Fu, J., et al. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.08.008 · Cited by 18
“Moreover, deaths in the pembrolizumab/pomalidomide/dexamethasone groupwere disproportionately owing to AEs compared with the control group (n ¼ 13 vs. n ¼ 3, respectively), and the study was ended early owing to the unfavorable benefit-to-risk profile.39 Similarly, the phase III KEYNOTE-185 study of pembrolizumab/lena…”
BackgroundInfluentialCottini, F., Huang, Y., Williams, N., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.575168 · Cited by 18
Immunotherapy of Multiple Myeloma: Promise and Challenges
Abramson, H. N. (2021) · ImmunoTargets and Therapy · doi:10.2147/itt.s306103 · Cited by 19
Yimer, H. A., Melear, J. M., Faber, E. A., Bensinger, W., Burke, J. M., Narang, M., Stevens, D. A., Gray, K. S., Lutska, Y., Bobba, P., et al. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2076847 · Cited by 18
“In MAIA (median follow-up, 47.9months), daratumumab plus lenalidomide and dexamethasone (D-Rd) led to an estimated 36-month PFS rate of 67.4% [20].”
InfluentialSelf-citationPerrot, A., Delimpasi, S., Spanoudakis, E., Frølund, U. C., Belotti, A., Oriol, A., Moreau, P., McFadden, I., Xia, Q., Arora, M., et al. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2322030 · Cited by 17
“Treatment strategies for first-line therapy have expanded to include multi-drug regimens containing some combination of proteasome inhibitor (PI), lenalidomide, anti-CD38 monoclonal antibody (mAb), and dexamethasone [2–4].”
BackgroundSelf-citationMonoclonal immunoglobulin crystalline nephropathies
Nasr, S. H., Sirac, C., Leung, N., et al. (2024) · Kidney International · doi:10.1016/j.kint.2024.02.027 · Cited by 17
Hadidi, S. A., Miller-Chism, C. N., Kamble, R. T., & Mims, M. P. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.04.004 · Cited by 17
Metadata
- Authors
- Facon, T., Kumar, S., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., Goldschmidt, H., O’Dwyer, M., Perrot, A., Venner, C. P., Weisel, K., Mace, J. R., Raje, N., Attal, M., Tiab, M., Macro, M., Frenzel, L., Leleu, X., Ahmadi, T., Chiu, C., Wang, J., Van Rampelbergh, R., Uhlar, C. M., Kobos, R., Qi, M., & Usmani, S. Z.
- Affiliations
- Université de Lille (FR)
- Mayo Clinic (US)
- University of Southern Denmark (DK)
- The University of Texas MD Anderson Cancer Center (US)
- University of Calgary (CA)
- Karolinska University Hospital (SE)
- The University of Melbourne (AU)
- From University of Lille, Centre Hospitalier Universitaire (CHU) Lille, Service des Maladies du Sang, Lille (T.F.), Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.), Department of Hematology, Hospital Haut Leveque, University Hospital, Pessac (C.H.), Hematology Department, University Hospital, Vandoeuvre lès Nancy (A.P.), Service d’Hématologie, CHU de Toulouse–Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse (M.A.), Department of Hematology, Vendée Hospital, La...
- University of Alberta (CA)
- Hôpital Necker-Enfants Malades (FR)
- Inserm (FR)
- ORCID
- Facon, Thierry
- Kumar, Shaji
- Plesner, Torben
- Orlowski, Robert Z.
- Moreau, Philippe
- Bahlis, Nizar
- Basu, Supratik
- Nahi, Hareth
- Hulin, Cyrille
- Quach, Hang
- Goldschmidt, Hartmut
- Perrot, Aurore
- Venner, Christopher P.
- Weisel, Katja
- Raje, Noopur
- Attal, Michel
- Macro, Margaret
- Frenzel, Laurent
- Leleu, Xavier
- Ahmadi, Tahamtan
- Chiu, Christopher
- Wang, Jianping
- Qi, Ming
- Usmani, Saad Z.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-05-30
- Volume
- 380
- Issue
- 22
- Pages
- 2104-2115
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC10045721
- OpenAlex
- W2947874495
- Cited by
- 1,045
- References
- 32
- Citations by year
- 2026: 105 · 2025: 111 · 2024: 107 · 2023: 130 · 2022: 145 · 2021: 208 · 2020: 195 · 2019: 39
- FWCI
- 107.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (acceptedVersion, other-oa)
- Wolverhampton Intellectual Repository and E-Theses (University of Wolverhampton) (acceptedVersion, cc-by-nc-nd)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- Funders
- Janssen Research and Development (-)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- daratumumab, lenalidomide, dexamethasone, newly diagnosed multiple myeloma, progression-free survival, minimal residual disease, complete response, neutropenia, adverse events, autologous stem cell transplantation ineligibility, monoclonal antibody therapy, combination therapy, anemia, lymphopenia
- MeSH terms
- Lenalidomide, Progression-Free Survival, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Female, Humans, Male, Middle Aged, Multiple Myeloma, Neutropenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
